Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Do we need a new classification for choroidal neovascularization in age-related macular degeneration?

Literature DB >> 20924258

Do we need a new classification for choroidal neovascularization in age-related macular degeneration?

K Bailey Freund, Sandrine A Zweifel, Michael Engelbert.

Abstract

Mesh：

Year: 2010 PMID： 20924258 DOI： 10.1097/IAE.0b013e3181e7976b

Source DB: PubMed Journal: Retina ISSN： 0275-004X Impact factor: 4.256

Keyword Cloud
Cited

× No keyword cloud information.

91 in total

1. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration.

Authors: Cheolmin Yun; Jaeryung Oh; Jaemoon Ahn; Soon-Young Hwang; Boram Lee; Seong-Woo Kim; Kuhl Huh
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2016-01-19 Impact factor: 3.117

2. Quantitative classification of eyes with and without intermediate age-related macular degeneration using optical coherence tomography.

Authors: Sina Farsiu; Stephanie J Chiu; Rachelle V O'Connell; Francisco A Folgar; Eric Yuan; Joseph A Izatt; Cynthia A Toth
Journal: Ophthalmology Date: 2013-08-29 Impact factor: 12.079

3. Imaging retinochoroidal anastomosis via spectral-domain optical coherence tomography.

Authors: S Pilli; C O'Brien; A J Lotery
Journal: Eye (Lond) Date: 2013-06-21 Impact factor: 3.775

4. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study).

Authors: A T Fung; N Kumar; S K Vance; J S Slakter; J M Klancnik; R S Spaide; K B Freund
Journal: Eye (Lond) Date: 2012-08-10 Impact factor: 3.775

9. Retention of good visual acuity in eyes with neovascular age-related macular degeneration and chronic refractory subfoveal subretinal fluid.

Authors: Kavita V Bhavsar; K Bailey Freund
Journal: Saudi J Ophthalmol Date: 2014-03-12

10. Optical coherence tomography angiography of types 1 and 2 choroidal neovascularization in age-related macular degeneration during anti-VEGF therapy: evaluation of a new quantitative method.

Authors: Henrik Faatz; Marie-Louise Farecki; Kai Rothaus; Frederic Gunnemann; Matthias Gutfleisch; Albrecht Lommatzsch; Daniel Pauleikhoff
Journal: Eye (Lond) Date: 2019-04-10 Impact factor: 3.775

Do we need a new classification for choroidal neovascularization in age-related macular degeneration?

1. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration.

2. Quantitative classification of eyes with and without intermediate age-related macular degeneration using optical coherence tomography.

3. Imaging retinochoroidal anastomosis via spectral-domain optical coherence tomography.

4. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study).

5. Three dimensional spectral domain optical coherence tomography features of retinal-choroidal anastomosis.

6. Characteristics of type 1 and 2 CNV in exudative AMD in OCT-Angiography.

7. OCT angiography and sequential quantitative analysis of type 2 neovascularization after ranibizumab therapy.

8. Is ellipsoid zone integrity essential for visual recovery in myopic neovascularization after anti-VEGF therapy?

9. Retention of good visual acuity in eyes with neovascular age-related macular degeneration and chronic refractory subfoveal subretinal fluid.

10. Optical coherence tomography angiography of types 1 and 2 choroidal neovascularization in age-related macular degeneration during anti-VEGF therapy: evaluation of a new quantitative method.